Gary S. Gray

TL;DR: A counter-receptor of CD28 and CTLA-4 is cloned, termed B7-2, which also costimulates IL-2 production and T cell proliferation and is likely to provide a critical early costimulatory signal determining if the T cell will contribute to an immune response or become anergic.

TL;DR: It is concluded that CTLA4-Ig and 5C8 can both prevent and reverse acute allografted rejection, significantly prolonging the survival of major histocompatibility complex-mismatched renal allografts in primates without the need for chronic immunosuppression.

TL;DR: Recombinant human platelet factor-4 (rhPF4), purified from Escherichia coli, inhibited blood vessel proliferation in the chicken chorioallantoic membrane in a dose-dependent manner and suggested that the angiostatic effect was due to specific inhibition of growth factor-stimulated endothelial cell proliferation.

TL;DR: Results suggest that blockade of costimulatory signals by CTLA4Ig or anti-B7-2 acts early in disease development, after insulitis but before the onset of frank diabetes, and that different members of the B7 family have distinct regulatory functions during the development of autoimmune diabetes.

TL;DR: In a human antigen-specific model system, when tetanus toxoid peptide antigen is presented by cells cotransfected with HLA-DR7 and B7, optimal T-cell proliferation and interleukin 2 production result, demonstrating that it is possible to induce antigen- specific clonal tolerance in human T cells that have been previously sensitized to antigen.